Jump to Main Content
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
- Granadillo, Milaid, Vallespi, Maribel G., Batte, Aileen, Mendoza, Osmany, Soria, Yordanka, Lugo, Victoria M., Torrens, Isis
- Vaccine 2011 v.29 no.5 pp. 920-930
- Limulus polyphemus, Papillomaviridae, T-lymphocytes, antigens, cell membranes, humans, mice, models, peptides, uterine cervical neoplasms, vaccination, vaccines
- The ultimate success of cancer vaccination is dependent upon the generation of tumor-specific CTLs. In this study, we designed and evaluated a novel fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32–51 of the Limulus polyphemus protein (LALF₃₂–₅₁) linked to human papillomavirus (HPV) 16 E7 antigen (LALF₃₂–₅₁–E7). We demonstrated that LALF₃₂–₅₁ penetrates the cell membrane and delivers E7 into cells. In a preclinical model of HPV16-induced cervical carcinoma we showed that vaccination with adjuvant-free LALF₃₂–₅₁–E7 fusion protein significantly improves the presentation of E7-derived peptides to T-cells in vitro and induces suppression of tumor growth.